Would you ever choose FOLFOXIRI over FOLFOX for high risk Stage III colon adenocarcinoma with multiple adverse prognostic features?

Topics: Gastrointestinal Cancers • Medical Oncology • Colorectal Cancer

Does the presence of BRAF mutation affect your decision?

Answer from: Medical Oncologist at Community Practice

We are frequently confronted in the clinic with a patient with "high risk" stage 3 colon cancer, most commonly with multiple positive lymph nodes. While our gut reaction might be to treat "aggressively", there are no data supporting FOLFOXIRI in the adjuvant setting. In fact, several adj...

Comments

Medical Oncologist at Advocate Lutheran General Hospital
Thank you, @Steven J. Cohen. I had similar thought...

Medical Oncologist at Advocate Lutheran General Hospital
Agree with your comments, @Axel Grothey. Appreciat...

Answer from: Medical Oncologist at Community Practice

I fully agree with Dr Grothey’s expertise on use of CAPOX (preferred) or FOLFOX until further data is available. Beyond the planned trials Dr Grothey referred to, a phase III trial in France and Canada should also help elucidate this clinically important question. The IROCAS study (NCT02967289...

Related Questions